Learning Objectives for 2005 Annual Meeting

At the conclusion of this symposium, the learner should be able to:

Explain the expanding role of imaging within the practice of brachytherapy. This will be accomplished through the exploration of advances in treatment technique and dosimetric evaluation as well as treatment outcome in gynecologic, breast, prostate and endovascular brachytherapy.

Review all aspects of brachytherapy application, including indications for use, technical considerations, quality assurance programs and outcome evaluations.

CME Statement for 2005 Annual Meeting

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the School of Medicine, Virginia Commonwealth University, Medical College of Virginia Campus (VCU), and the American Brachytherapy Society (ABS).

The School of Medicine, Virginia Commonwealth University, Medical College of Virginia Campus (VCU) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

Physicians may claim up to 21.5 hours in Type 1 or Type 2 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license.

VCU designates this educational activity for a maximum of 21.5 hours in category 1 credit toward the AMA’s Physician Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

Conflict of Interest and Off-Label / Disclosure Statement

Presenters at this conference will disclose any conflict of interest or their intention to discuss off-label use, if applicable, in accordance with ACCME Standards and FDA requirements. Conflict of interest will be disclosed in print or in the final meeting materials.
# ABS Past and Future Presidents

2005  Frank A. Vicini, MD  
2004  Michael J. Zelefsky, MD  
2003  Beth A. Erickson, MD  
2002  Colin Orton, Ph.D.  
2001  David Beyer, MD  
2000  James Fontanesi  
1999  Subir Nag, MD  
1998  Kent Wallner, MD  
1996-1997  Burton L. Speiser, MD  
1995  Arthur T. Porter, MD  
1994  John C. Blasko, MD  
1993  Louis B. Harrison, MD  
1992  Alvaro A. Martinez, MD  
1991  Kenneth H. Luk, MD  
1990  Peter A. Fleming, MD  
1989  Dattatreyudu Nori, MD  
1988  Karen K. Fu, MD  
1987  Luis Delclos, MD  
1986  Basil S. Hilaris, MD  
1985  Don R. Goffinet, MD  
1984  A.M. Nisar Syed, MD  
1983  Thomas C. Gates, MD  
1982  Ajmel A. Puthawala, MD  
1981  Paul Y. M. Chan, MD  
1980  Aaron G. Fingerhut, MD  
1979  David L. Neblett, MS  
1978  Harvey S. Frey, MD, Ph.D.

# Wednesday Night Welcome Reception

*Everyone is invited to attend the Welcome Reception on Wednesday night at the Hyatt Regency. We hope to see you there!*
**Tuesday, May 31**
1:00 pm – 6:00 pm  Exhibitor set-up and registration
12:00 noon – 6:00 pm  Registration

**Wednesday, June 1**
7:00 am – 5:00 pm  Registration
7:00 am – 5:00 pm  Commercial Exhibits
7:00 – 7:30 am  Continental Breakfast
7:30 – 8:30 am  **Gynecologic Brachytherapy Refresher Course**
Akila N. Viswanathan, MD
Brigham and Women’s Cancer Center
Boston, MA
8:30 – 10:15 am  **Issues in Gynecologic Brachytherapy**
Moderator: Patricia J. Eifel, MD
MD Anderson Cancer Center
Houston, TX
Panelists:
- **Patterns of Care for Adjuvant Therapy of Endometrial Cancer: Results of an ABS Survey**
  William Small, Jr., MD
  Northwestern Memorial Hospital
  Chicago, IL
- **Future of Pulsed Dose-Rate Techniques**
  Patricia J. Eifel, MD
  MD Anderson Cancer Center
  Houston, TX
- **Indications and Techniques for Vaginal Cuff Radiation**
  Manjeet Chadha, MD
  Beth Israel Medical Center
  New York, NY
10:15 – 10:40 am  Refreshment Break
10:40 – 11:30 am  **Proffered Papers – GYN**
Moderators: Kaled M. Alektiar, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
- D. Jeffrey Demanes, MD
  California Endocurietherapy Medical Corp.
  Oakland, CA
10:40 am  Dose Volume Analyses Of Gastrointestinal Complication After Brachytherapy For Gynecological Malignancy
I-Chow J. Hsu, MD,¹ Albert Chan, C.M.D, R.T.T.,¹
10:50 am  Physiologic Volume Reduction Of Primary Cervical Carcinoma
Perry W. Grigsby, MD,¹ Lilie L. Lin, MD,¹ Jane Yang, MD,¹ Imran Zoberi, M.D.,¹
Tom R. Miller, MD,²
11:00 am  Primary Treatment Of Medically Inoperable Endometrial Cancer With Multi-Channel Uterine (Rotte-Y) Applicator
Ajay K. Bhatnagar, MD, Sushil Beriwal, MD, Dwight E. Heron, MD, Kristina Gerszten, MD, Raj Selvaraj, Ms, Robert Mogus, John Comerci, MD.

11:10 am  Mr Image-Guided Interstitial Brachytherapy For Recurrent Endometrial Carcinoma
Akila N. Viswanathan, MD, MPH, Robert Cormack, PhD, Desmond O’farrell, Cynthia Tanaka, Clare Tempany, MD.

11:20 am  Intraperitoneal Radioactive Phosphorus (32p) And Vaginal Brachytherapy As Adjuvant Treatment For Uterine Papillary Serous Carcinoma And Clear Cell Carcinoma: The Indiana University Experience
Achilles J. Fakiris, MD, Marcus E. Randall, MD, Katherine Y. Look, MD, David H. Moore, MD, Shailaja R. Reddy, MD, Simon S. Lo, MD, Higinia R. Cardenes, MD, PhD.

11:30 am – 12:00 noon  ABS Presidential Address: Frank A. Vicini, MD

12:00 noon – 1:15 pm  Lunch: Attendees on their own

12:00 noon – 1:00 pm  Residents’ Luncheon (Sponsored by Oncura) Brachytherapy Marketing
Kent E. Wallner, MD
Puget Sound Health Care System
Seattle, WA

1:15 – 1:45 pm  Ulrich Henschke Memorial Lecture
(Ulrich Henschke Award Sponsored by Best Medical International, Inc.)
Alvaro A. Martinez, MD
William Beaumont Hospital
Royal Oak, MI

1:45 – 3:15 pm  Update on Breast Brachytherapy Outcome Data/Protocols
Moderator: Douglas W. Arthur, MD
VCU Medical Center
Richmond, VA

Panelists: Update on NSABP B-39/RTOG 0413 Protocol
Julia R. White, MD
Medical College of Wisconsin
Milwaukee, WI

European Phase III Protocols
Csaba Polgar, MD
National Institute of Oncology
Budapest, Hungary

MammoSite™ RTS Data
Martin E. Keisch, MD
Mt. Sinai Comprehensive Cancer Center
Miami Beach, FL

Update of RTOG 95-17 Data
Robert R. Kuske, Jr., MD
Arizona Oncology Services
Scottsdale, AZ

3:15 – 3:40 pm  Refreshment Break
3:45 – 4:45 pm  Proffered Papers – Breast, Head and Neck

Co-moderators:  
Vijay Kini, MD  
Valley Radiotherapy Associates  
Fullerton, CA

Rakesh Patel, MD  
University of Wisconsin  
Madison, WI

Csaba Polgar, MD  
National Institute of Oncology  
Budapest, Hungary

3:45 pm  
Post-Operative High Dose Rate Brachytherapy In The Management Of Resected T1 And T2 Oral Cavity Cancer With Positive Or Close Margins  
David Donath, MD, FRCPMD, FRCP, Felix Nguyen, MD, FRCP,  
Bernard Fortin, MD, FRCP, Louis Guertin, MD, FRCS,  

3:55 pm  
Management Of Oral Tongue Carcinoma With External Beam Radiotherapy And Interstitial Brachytherapy Boost: Is Limited Surgery Necessary To Improve Outcome?  
Omur Karakoyun Celik, M.D., Charles M. Norris, M.D., Roy Tishler, M.D., Anand Mahadevan, M.D., John R Clark, M.D., Paul M Busse, M.D., Ph.D.,  

4:05 pm  
A German-Austrian Multicenter Phase II Trial: Interstitial Brachytherapy Only After Breast Conserving Surgery – A 4-Year Up-Date Analysis  
Vratislav Strnad, Prof.MD, Oliver J. Ott, MD, Richard Poetter, Prof. MD, Guido Hildebrandt, MD, Joe Hammer, MD, Michael Lotter, PhD,  
Rolf Sauer, Prof. MD,  

4:15 pm  
The Allegheny General Hospital Breast Preservation Experience Utilizing Repeat Tyllectomy And Re-Irradiation Brachytherapy For Isolated In-Breast Tumor Recurrence  
Mark G. Trombetta, M.D., Thomas B. Julian, M.D., Tanuja A Bhandari, M.D., E Day Werts, PhD, David S. Parda, M.D.,  

4:25 pm  
Long-Term Results Of Accelerated Partial Breast Irradiation (Apbi) Via Interstitial Brachytherapy As The Sole Radiation Modality For Treatment Of Early Stage Breast Cancer  
Peter Y. Chen, MD, Frank A. Vicini, MD, Pamela Benitez, MD, Jane Pettinga, MD, Michelle Wallace, RN, Alvaro A. Martinez, MD,  

4:35 pm  
Fat Necrosis Following Partial Breast Irradiation Versus Standard Whole Breast Radiotherapy: 4-Year Results Of A Randomized Study  
Katalin Lovey, M.D., Tibor Major, M.Sc., Ph.D., Janos Fodor, M.D., D.Sc., Zoltan Sulyok, M.D., Zoltan Takacs-Nagy, M.D., Csaba Polgar, M.D., Ph.D.,  

4:45 – 5:30 pm  
How To Make Sense of the Data for Local Control in Early Breast Cancer  
Abram Recht, MD  
Beth Israel Deaconess Medical Center  
Boston, MA

6:30 – 7:30 pm  
Welcome Reception at the Hyatt Regency
Thursday, June 2

7:00 am – 5:00 pm  Registration
6:30 am – 5:00 pm  Commercial Exhibits
6:30 – 7:00 am  Continental Breakfast
7:00 – 8:00 am  **Breast Brachytherapy Refresher Course**
                   Douglas W. Arthur, MD
                   VCU Medical Center
                   Richmond, VA

8:00 – 9:30 am  **Brachytherapy and the Law**

Moderator:  W. Robert Lee, MD
            Wake Forest University
            Winston-Salem, NC

Panelists:  **Definition of Medical Negligence**
            James W. Saxton, Esq.
            Chairman, Health Litigation Group
            Stevens & Lee
            Lancaster, PA

            **Legal Issues in Brachytherapy**
            W. Robert Lee, MD
            Wake Forest University
            Winston-Salem, NC

            **Prostate Brachytherapy Malpractice Issues**
            Kent E. Wallner, MD
            Puget Sound Health Care System
            Seattle, WA

9:30 – 9:55 am  Refreshment Break

9:55 – 10:55 am  **The Impact of Imaging on Brachytherapy Treatment Planning**

            **Using MRI to Enhance the Accuracy of Target Conturing**
            Patrick William McLaughlin, MD
            The University of Michigan
            Southfield, MI

            **Imaged Based Treatment for Gynecologic Brachytherapy**
            Richard Pötter, MD
            Medical University of Vienna
            Vienna, Austria

10:55 am – 12:15 pm  **Proffered Papers – Prostate I**

Outcomes with Prostate Brachytherapy

Moderators:  John Sylvester, MD
             Seattle Prostate Institute
             Seattle, WA

10:55 am  Impact Of Percent Positive Core Biopsies On Permanent Prostate Brachytherapy
           (Ppb) Outcomes By Risk Group
           Gary M. Kirsh, M.D.,¹ Peter R. Fried, M.D.²
11:05 am  Percentage Positive Biopsies Is Associated With Freedom From Biochemical Recurrence Following Low Dose Rate Prostate Brachytherapy Alone
Peter J. Rossi, MD,1 Peter E. Clark, MD,1 David L. McCullough, MD,1 W. Robert Lee, MD, MS,1

11:15 am  20 Gy vs 44 Gy Supplemental Beam Radiation With Pd-103 Prostate Brachytherapy: Early Biochemical Outcomes From A Prospective Randomized Multi-Center Trial
Peter F. Orio, DO,1 Kent E. Wallner, MD,1,2 Gregory Merrick, MD,3 Lawrence True, MD,1,3 Dan Reed, DO,1 Sutlief Steve, PhD,2 Wayne Butler, PhD,3

11:25 am  Dose Escalation Using An Hdr Brachytherapy Boost In An Accelerated Treatment Course Improves Overall Survival For Patients With Unfavorable Prostate Cancer
Alvaro A. Martinez, M.D., F.A.C.R.,1 Carlos Vargas, M.D.,1 Thomas P. Boike, B.S.,1 Gregory Edmundson, M.S.,1 Peter Y. Chen, M.D.,1 Gary S. Gustafson, M.D.1

11:35 am  Does Age At Diagnosis Affect Outcome For Men Treated By Brachytherapy Versus Surgery For Clinically Localized Prostate Cancer?
Jonathan D. Tward, MD, PhD,1 Aniko Szabo, PhD,2 Dennis C. Shrieve, MD, PhD,1 David K. Gaffney, MD, PhD,1

11:45 am  The Impact Of Prostate Brachytherapy On Regional, Racial, And Age-Related Patterns of Treatment For Clinically Localized Prostate Cancer
Mohamed A. Elshaikh, MD,1 Laurel A. Copeland, Ph.D,2 James Jackson, Ph.D,4 Louis A. Penner, Ph.D,1 Willie Underwood III, MD,1

12:15 – 1:40 pm  ABS Member Lunch  (Sponsored by Nucletron) and ABS Annual Business Meeting (members-only)

1:40 – 2:00 pm  The Second Era of Prostate Brachytherapy: 1951-1985
Jesse Aronowitz, MD
University of Massachusetts
Boston, MA

2:00 – 3:00 pm  Androgen Deprivation Therapy in Prostate Brachytherapy – Is It Necessary?
Moderator: Juanita M. Crook, MD
Princess Margaret Hospital
Toronto, Ontario, Canada
Panelists:
Pro:
Richard G. Stock, MD
Mt. Sinai Medical Center
New York, NY

Con:
Gregory S. Merrick, MD
Schiffler Cancer Center
Wheeling, WV

3:00 – 4:00 pm  Combining External Beam and Brachytherapy for Prostate Cancer – How and Why
Moderator: Gerard Morton, MD
Toronto Sunnybrook Regional Cancer Center
Toronto, Ontario, Canada
Panelists:
Pro:
Bradley R. Prestidge, MD
Texas Cancer Clinic
San Antonio, TX
Con:
John C. Blasko, MD
Seattle Prostate Institute
Seattle, WA

4:00 – 5:15 pm
Quality of Life After Prostate Treatment – What Have We Learned?
Moderator:  Michael J. Zelefsky, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
Panelists:
James A. Talcott, MD
Massachusetts General Hospital Cancer Center
Boston, MA
Michael J. Zelefsky, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

6:30 – 9:30 pm
Gala Event in San Francisco’s Carmelian Room (top floor of the Bank of America Building; Sponsored by Varian BrachyTherapy; meet in hotel lobby at 6:15 for bus service)

Friday, June 3
7:00 – 9:00 am
Registration
7:00 am – noon
Commercial Exhibits
7:00 – 7:30 am
Continental Breakfast
7:00 – 8:00 am
Prostate Brachytherapy Refresher Course
Outcomes and Comparisons With Other Modalities
Brian J. Davis, MD
Mayo Clinic
Rochester, MN
Predictors of Toxicity and Management of Side Effects After Brachytherapy
Daniel Ash, MD
Cookridge Hospital
Leeds, UK

8:00 – 9:20 am
Proffered Papers – Prostate II
Prostate Brachytherapy: Dosimetry Issues and Treatment Modality
Moderators:  Daniel Ash, MD
Cookridge Hospital
Leeds, UK
Daniel Shasha, MD
Phillips Ambulatory Care Center
New York, NY

8:00 am
A Six Physician Comparison Of Post Prostate Implant Ct Contours T o An MrI Standard
Patrick W. McLaughlin, MD,1 Vrinda Narayana, PhD,1 Ted R. Jackson, PhD,2 Juanita M. Crook, MD,3 William R. Lee, MD,4 Jeff M. Michalski, MD,5 Bradley R. Prestidge, MD,6 Michael J. Zelefsky, MD,7
8:10 am  
Variability Of Prostate Brachytherapy Preimplant Dosimetry: A Multi-Institutional Analysis  
Gregory S. Merrick, M.D.,1 Wayne M. Butler, PH.D.,1 Kent E. Wallner, M.D.,1  
John C. Blasko, M.D.,1 Jeff Michalski, M.D.,1 Jesse Aronowitz, M.D.,1  
Peter Grimm, D.O.,1 Brian J. Moran, M.D.,1 Patrick McLaughlin, M.D.,1  
Jacqueline Usher, B.S.,1 Jonathan Lief, PH.D.,1 Zachariah Allen, M.S.,1

8:20 am  
Intraoperative Fluoroscopic-Based Dosimetry In Prostate Brachytherapy Patients  
Daniel R Reed, DO,1,2 Kent E. Wallner, MD,1,2 Sreeram Narayanan, PhD,1,2  
Gregory Merrick, MD,3 Wayne Butler, PhD,3 Steve Sutlief, PhD,2  
Paul Cho, PhD.1,2

8:30 am  
Dosimetric Comparison Of Three Intra-Operative Computer Planning Options  
For Permanant Seed Implantation Of The Prostate  
Adam Raben, MD,1 Sarah Sammons, BA,1 Sang Sim, MD,2 Hansen Chen, MS,2  
Alex Hanlon, PhD,2 Abhirup Sarkar, MS,1 Arnold Grebler, MD,2  
Jules Geltzeiler, MD,2 Bruce Benge, MD,2 Andrew Glick, MD,2 Alex Hanlon, PhD,1  
Paul Koprowski, BA,1 Viroon Donavanik, MD,1

8:40 am  
Prostate Brachytherapy-Induced Urethral Strictures  
Gregory S. Merrick, MD,1,2 Wayne M Butler, PHD,1,2 Kent E. Wallner, MD,3  
Robert W. Galbreath, PHD,1,2 Richard L. Anderson, RTT, CMD,1  
Zachariah A. Allen, MS.1,2

8:50 am  
I-125 Versus Pd-103 For Low Risk Prostate Cancer: Morbidity Outcomes From A  
Prospective Randomized Multi-Center Controlled Trial  
Andrew Herstein,1 Kent Walmer, M.D.,1,2 Gregory Merrick, M.D.,3  
Paul Mitsuyama, M.D.,1,2 Julius Armstrong, RTT,2 Lawrence True, M.D.,4  
William Cavanagh, B.A.,2 Wayne Butler, PH.D.3

9:00 am  
Risk Factors Associated With Urinary Retention Following Permanent 125i  
Prostate Brachytherapy: A Retrospective Multivariate Analysis Of 1,286  
Monotherapy Patients  
David Linstadt, MD,1 Mark Logsdon, MD,1 Steve Workman, MD,2  
Larry Goldman, MD,2 Michael Russo, MD,2 Deepak Chabra, MD,2  
Dwight Stickney, MD.1

9:10 am  
Predictive Factors For Erectile Dysfunction In Men With Prostate Cancer  
Following Prostate Brachytherapy: Is Dose To The Penile Bulb Important?  
Graham Macdonald, MD,1 Mira Keyes, MD,1 Alexandra Kruk, RTT,2  
Graeme Duncan, MD,1 Veronika Moravan, Msc,3 James Morris, MD.1

9:20– 9:40 am  
Refreshment Break

9:40 – 11:10 am  
Proffered Papers - Physics

Moderators:  
Ali S. Meigooni, Ph.D.  
University of Kentucky Medical Center  
Lexington, KY

Phillip Devlin, MD  
Harvard Medical School  
Boston, MA

9:40 am  
On The Inadverted Under−Dosing Of A Complex Spheriod Instilled With P−32  
Chromic Phosphorous Colloid  
Charles D. Hechtman, Z Li, Perry Grigsby and Mark Dicocco, Washington University,  
St. Louis, MO
9:52 am  Calculated And Measured Brachytherapy Dosimetry Parameters In Water For The Xoft Axxent X–ray Source: An Electronic Brachytherapy Source  Mark J. Rivard¹, Stephen D. Davis², Larry A. DeWerd², Thomas W. Rusch³ and Steve Axelrod³. ¹Tufts–New England Medical Center, Boston, MA; ²University of Wisconsin, Madison, WI and ³Xoft, Inc., Fremont, CA

10:04 am  Automatic Calculation Of A Modified Conformal Index (Coin) For Optimal Dose Prescription Of Hdr Prostate Implants  Joseph Hanley, Igor Rebo, Alois M. Ndlovu, Joseph C. Barbiere, John J. Napoli, Alex Kapulusky and Glen Gejerman. Hackensack University Medical Center, Hackensack, NJ.

Physics Panel: Targeting and Prescription in Prostate Brachytherapy

Moderator:  Phillip M. Devlin, MD  Harvard Medical School  Boston, MA

Panelists:  Recent Advances in Image-Guided Targeting in Prostate Brachytherapy  Robert Cormack, Ph.D.  Harvard Medical School  Boston, MA

Specification in Prescriptions  Wayne M. Butler, Ph.D.  Wheeling Hospital / Schiffler Cancer Center  Wheeling, WV

Reevaluation of Prescribed Doses in Prostate Brachytherapy – Historical Developments  Jeffrey F. Williamson, Ph.D.  Virginia Commonwealth University  Richmond, VA

11:10 am – 12:15 pm  Brachytherapy Economics and Practical Coding Considerations

Moderator:  D. Jeffrey Demanes, MD  California Endocurietherapy Medical Corp.  Oakland, CA

Panelists:  D. Jeffrey Demanes, MD  California Endocurietherapy Medical Corp.  Oakland, CA

James E. Hugh, III, MHA  American Medical Accounting and Consulting, Inc.  Marietta, GA

Ron DiGiaimo, MBA, BSHA, R.T. (R)(T)  Revenue Cycle, Inc.  Austin, TX

12:15 pm  Meeting adjourns

* Speakers, Topics and Times Subject to Change; Views Expressed are Not Necessarily the Views of the American Brachytherapy Society.
## Meeting Space Key

<table>
<thead>
<tr>
<th>Day</th>
<th>Function</th>
<th>Room(s) / Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday – Friday</td>
<td>Registration</td>
<td>Market Street Foyer</td>
</tr>
<tr>
<td>Wednesday</td>
<td>Commercial Exhibits/Breaks</td>
<td>Pacific Concourse</td>
</tr>
<tr>
<td>Wednesday</td>
<td>General Sessions</td>
<td>Grand Ballroom BC</td>
</tr>
<tr>
<td>Wednesday</td>
<td>Speaker Ready Room</td>
<td>Regency B</td>
</tr>
<tr>
<td>Wednesday</td>
<td>Residents’ Luncheon (for Residents only)</td>
<td>Hospitality Room</td>
</tr>
<tr>
<td>Wednesday</td>
<td>Editorial Board Meeting</td>
<td>Marina Room</td>
</tr>
<tr>
<td>Wednesday</td>
<td>Welcome Reception</td>
<td>Atrium 3 - 4</td>
</tr>
<tr>
<td>Wednesday</td>
<td>Posters</td>
<td>Pacific Concourse, Seacliff AB</td>
</tr>
<tr>
<td>Thursday</td>
<td>Commercial Exhibits/Breaks</td>
<td>Pacific Concourse</td>
</tr>
<tr>
<td>Thursday</td>
<td>General Sessions</td>
<td>Grand Ballroom BC</td>
</tr>
<tr>
<td>Thursday</td>
<td>Speaker Ready Room</td>
<td>Regency B</td>
</tr>
<tr>
<td>Thursday</td>
<td>Annual Business Meeting and Member Lunch (members only)</td>
<td>Garden Room</td>
</tr>
<tr>
<td>Thursday</td>
<td>Posters</td>
<td>Pacific Concourse, Seacliff AB</td>
</tr>
<tr>
<td>Thursday</td>
<td>Gala Event</td>
<td>Carnelian Room, Bank of America Building 6:30 to 9:30 pm Meet in hotel lobby at 6:15 pm for bus service</td>
</tr>
<tr>
<td>Friday</td>
<td>Commercial Exhibits/Breaks</td>
<td>Pacific Concourse</td>
</tr>
<tr>
<td>Friday</td>
<td>General Sessions</td>
<td>Grand Ballroom BC</td>
</tr>
<tr>
<td>Friday</td>
<td>Speaker Ready Room</td>
<td>Regency B</td>
</tr>
<tr>
<td>Friday</td>
<td>Posters</td>
<td>Pacific Concourse, Seacliff AB</td>
</tr>
</tbody>
</table>
Acknowledgment of 2005 Annual Meeting Commercial Support

The American Brachytherapy Society would like to acknowledge the support, through an unrestricted educational grant, of the following organizations:

**Best Medical International** (Ulrich Henschke Memorial Award, attendee tote bags)

**Cytyc Surgical Products** (speaker travel)

**Nucletron** (ABS Membership Luncheon, Judith Stitt paper and poster awards)

**Oncura** (Resident Luncheon, Resident Travel Grant Awards, Resident Prostate Brachytherapy Fellowship Program)

**Varian BrachyTherapy** (Gala Event)

Annual Meeting Gala Event
*Sponsored by Varian BrachyTherapy*

The ABS would like to acknowledge the support of the 2005 Gala Event by Varian BrachyTherapy, through an unrestricted educational grant. This year’s event will be held at the famed Carnelian Room Restaurant on the top floor of the Bank of America World Headquarters building in downtown San Francisco. From the 52nd floor, relax with colleagues and see the sites of the city including the Golden Gate Bridge and the Bay Bridge. Enjoy light food, drinks and music while networking and talking with fellow attendees, exhibitors and guests. This event is included in the registration fee for attendees and guests, however exhibitors are required to register separately at a fee of $125. Join your colleagues for this year’s Gala Event.
The American Brachytherapy Society extends a sincere thank you to all of our corporate supporters and we encourage all attendees to visit with our exhibitors over the course of the meeting.

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
<th>Tabletop Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced Care Technologies</td>
<td>512</td>
<td></td>
</tr>
<tr>
<td>Alpha-Omega Services</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>AnazaoHealth Corporation</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>ASTRO</td>
<td>611</td>
<td></td>
</tr>
<tr>
<td>Bard Brachytherapy</td>
<td>301</td>
<td></td>
</tr>
<tr>
<td>Best Medical International</td>
<td>102</td>
<td></td>
</tr>
<tr>
<td>B-K Medical Systems</td>
<td>309</td>
<td></td>
</tr>
<tr>
<td>BSD Medical</td>
<td>104</td>
<td></td>
</tr>
<tr>
<td>Capintec</td>
<td>205</td>
<td></td>
</tr>
<tr>
<td>Computerized Medical Systems (CMS)</td>
<td>206</td>
<td>2</td>
</tr>
<tr>
<td>Cytce Surgical Products</td>
<td>207</td>
<td></td>
</tr>
<tr>
<td>(formerly Proxima Therapeutics)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elsevier Publishing</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Harvard Medical School Dept. of CME</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Implant Sciences Corporation</td>
<td>510</td>
<td></td>
</tr>
<tr>
<td>IsoAid LLC</td>
<td>207</td>
<td></td>
</tr>
<tr>
<td>IsoRay Medical</td>
<td>201</td>
<td></td>
</tr>
<tr>
<td>Mentor</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Mick Radio Nuclear Instruments</td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>North American Scientific</td>
<td>202</td>
<td></td>
</tr>
<tr>
<td>Nucletron</td>
<td>508</td>
<td></td>
</tr>
<tr>
<td>Oncura</td>
<td>311</td>
<td></td>
</tr>
<tr>
<td>Pro-Qura</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>RadioMed Corporation</td>
<td>217</td>
<td></td>
</tr>
<tr>
<td>Theragenics Corporation</td>
<td>210</td>
<td></td>
</tr>
<tr>
<td>Varian Brachytherapy</td>
<td>303</td>
<td></td>
</tr>
<tr>
<td>Xoft</td>
<td>209</td>
<td></td>
</tr>
</tbody>
</table>
ABS Board of Directors
President: Frank A. Vicini, MD
Vice President: Douglas W. Arthur, MD
Secretary: W. Robert Lee, MD
Treasurer: Gregory S. Merrick, MD
Chairman: Michael J. Zelefsky, MD

Board Members-at-Large
William Bice, Ph.D.
Patricia J. Eifel, MD
Michael J. Katin, MD
Subir Nag, MD

Annual Meeting Scientific Program Committee
Frank A. Vicini, MD, Scientific Program Chair
Douglas W. Arthur, MD
W. Robert Lee, MD
Bruce R. Thomadsen, Ph.D.
Michael J. Zelefsky, MD

Annual Meeting Faculty
Kaled M. Alektiar, MD
Jesse Aronowitz, MD
Douglas W. Arthur, MD
Daniel Ash, MD
John C. Blasko, MD
Wayne M. Butler, Ph.D.
Manjeet Chadha, MD
Robert Cormack, MD
Juanita M. Crook, MD
Brian J. Davis, MD, Ph.D.
D. Jeffrey Demanes, MD
Phillip M. Devlin, MD
Ron Digiaino, MBA, BSHA, R.T. (R)(T)
Patricia J. Eifel, MD
James E. Hugh, III, MHA
Martin E. Keisch, MD
Vijay R. Kini, MD
Robert R. Kuske, MD
W. Robert Lee, MD
Alvaro Martinez, MD
Patrick W. McLaughlin, MD
Ali S. Meigooni, Ph.D.
Gregory S. Merrick, MD
Gerard C. Morton, MD
Csaba Polgar, MD
Richard Potter, MD
Bradley R. Prestidge, MD
Abram Recht, MD
James W. Saxton, Esq.
Daniel Shasha, MD
William Small, Jr., MD
Richard G. Stock, MD
John E. Sylvester, MD
James A. Talcott, MD
Akila N. Viswanathan, MD
Kent E. Wallner, MD
Julia R. White, MD
Jeffrey F. Williamson, Ph.D.
Michael J. Zelefsky, MD
ABS 2005 Awards: Ulrich Henschke Award
(sponsored by Best Medical International)

Alvaro Martinez, MD

Dr. Alvaro Martinez, MD, FACP, was born in Colombia, South-America and went to Medical School at The Javeriana University in Bogota, Colombia, graduating in 1968. Dr. Martinez came to the United States and did a residency in Radiation Oncology at Memorial Sloan Kettering Cancer Center, in New York City. He was the Chief Resident from 1973 to 1974, then went to Stanford University in 1974 as an Instructor, and then Assistant Professor, in the Department of Radiology. In 1981, he went to The Mayo Clinic and Mayo Medical School as an Associate Professor. In 1985, he became the Chairman of Radiation Oncology at William Beaumont Hospital and in 1998 was appointed Corporate Chairman of Beaumont Hospitals. He has received numerous honors and Medical Society recognitions. Dr. Martinez is a past-President of the American Brachytherapy Society and a past-President of the Michigan Society of Therapeutic Radiologists. He has served on multiple committees within ASTRO and within many other medical organizations. Dr. Martinez has co-authored more than 250 manuscripts in refereed medical journals, written 48 book chapters, and edited three brachytherapy books.

It is a pleasure to honor Dr. Alvaro Martinez with the 2005 Ulrich Henschke Award.

Past Ulrich Henschke Medal Recipients

1981 Basil Hilaris, MD
1981 A.M. Nisar Syed, MD
Primary Irradiation on the Management of Cancer of the Breast

1982 Lowell Anderson, PhD

1984 Bernard Perquin, MD
Account of French Fellows

1984 Eric Hall, DSc
The Biological Basis of Endocurietherapy

1985 Samuel Hellman, MD
Preservative Management of Breast Cancer

1986 Theodore L. Phillips, MD
Neurobrachytherapy, State of the Art

1988 Charles A.F. Joslen, MD
High Activity Source Afterloading in Gynecological Cancer and Its Future Prospects

1989 Professor Daniel Chassagre
Results of Oral Cancer Brachytherapy

1989 J. Frank Wilson, MD
Combined Modality Treatment with Brachytherapy

1990 Jack Fowler, DSc
The Role of Radiation Biology in Brachytherapy

1991 Carlos Perez, MD, FACP
A Historic Perspective and Challenges in Brachytherapy of the Uterine Cervix

1992 Willet Whitmore, MD
The Memorial Sloan Kettering Experience with 125-I for Prostate Cancer: 1970-1985

1993 Alain Gerbaulet, MD
Brachytherapy for Pediatric Malignancies

1994 Ravinder Nath, PhD
New Radionuclide Sources for Brachytherapy

1995 Colin Orton, PhD
The Dose-Rate Effect in Brachytherapy: Friend or Foe?

1999 Luis Delelos, MD
Irradiation for Malignant Tumors of the Vagina

2003 Louis B. Harrison, MD
26th Annual Meeting

Oncura Prostate Brachytherapy Fellowship Recipients

JC Abdou, MD, Ohio State University
Daniel Landis, MD, Ph.D., Harvard University
Laura Millender, MD, University of California San Francisco
Michael Miller, MD, E. Virginia
Michael Papagikos, MD, Wake Forest University
Doug Rivera, MD
Kevin Sanders, MD, MDACC
Vipul Thakkar, MD, Cleveland Clinic

Oncura Resident Travel Grant Award Recipients

J. Vito Antonucci, MD
Clinical Implication of PSA Bounce After Prostate Brachytherapy With or Without Neoadjuvant Androgen Deprivation

Ajay K. Bhatnagar, MD
Image Guided High-Dose Rate Interstitial Brachytherapy (HDRB) for Gynecological Malignancies

Cynthia J. Bryant, MD
Management of Brain Tumors With the Gliasite™ Radiation Therapy System: The Emory Experience

Moataz N. El-Ghamry, MD
Role of Interstitial Brachytherapy for Sphincter Preservation in Patients With Low Lying Rectal and Anal Cancers

William Foster, MD
Impact of Urinary Catheter and Leg Positioning on In Vivo Dosimetry in Patients Undergoing I-125 Seed Implantation

Christopher C. Goulet, MD
Geometrical Characterization of the Prostatic Urethra from CT Data Following Permanent Prostate Brachytherapy: Applications to Trans-Urethral Imaging and Brachytherapy Planning

Yasmin Hasan, MD
Technical Factors Affecting Early Toxicity and Cosmetic Outcome Following MammoSite Brachytherapy – The William Beaumont Hospital Experience

James L. Leenstra, MD
A Comparison of Prostate Dimensions and Volume In Patients Undergoing Radical Retropubic Prostatectomy, External Beam Radiation Therapy, or Permanent Prostate Brachytherapy for Localized Adenocarcinoma

Daniel R. Reed, DO
Rapid Strand™ vs. Loose (Iodine – 125 Seeds): A Prospective Randomized Trial

Samuel J. Rhoades, IV, MS
The Application of 90Sr / 90Y for the Prevention of Abdominal Adhesions

Naoyuki G. Saito, MD, PhD
MRI Based Observations of Anatomic Distortions Secondary to Permanent I-125 Prostate Implantation

Vipul V. Thakkar, MD
Factors Predicting for Acute Urinary Morbidity Following Permanent 125I Implantation of the Prostate: Insights from a Pooled Analysis of Two Prospective, Randomized Trials
ABS Posters (located in Pacific Concourse and Seacliff AB)

Gynecology

P-31
DVH ANALYSIS OF IMAGE-BASED BRACHYTHERAPY IN CERVICAL CANCER: POINT A VERSUS GTV PRESCRIPTION
Robert M Allbright, M.D., 1 Travers J McLoughlin, M.D., 1 Albert M Sabbas, Ph.D., 1 Fridon Kulidzhanov, Ph.D., 1 Yi-Shin Kuo, M.D., 2 Thomas A Caputo, M.D., 2 Dattatreyudu Nori, M.D., F.A.C.R., 1 1 Stich Radiation Center, New York-Presbyterian Hospital, New York, NY; 2 Department of Ob/Gyn, Division of Gynecologic Oncology, New York-Presbyterian Hospital, New York, NY.

P-32
INTEGRATED IMAGE-GUIDED HDR BRACHYTHERAPY AND CONCOMITANT COMPLEMENTARY IMRT FOR CANCERS OF THE UTERINE CERVIX
Jun Duan, Ph.D., 1 Robert Y Kim, M.D., 1 Sui Shen, Ph.D., 1 Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL.

P-33
TOXICITY OF CONCURRENT CISPLATIN AND BRACHYTHERAPY IN THE MANAGEMENT OF CERVIX CANCER
Richard C Zellars, MD, 1 Robert E Bristow, MD, 2 Robert Giuntoli, MD, 2 Fariba Asrari, MD, 1 Ginger Gardner, MD, 2 Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; 2 Kelly Gynecologic Oncology Service, Johns Hopkins Medical Institutions, Baltimore, MD.

P-34
HIGH DOSE RATE INTERSTITIAL BRACHYTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER
Thinh Phan, MD, 1 Ken Wong, MD, 1 Ajmel Puthawala, MD, 2 Anil Sharma, Ph.D., 2 Philip Disaia, MD, 2 Michael Berman, MD, 3 Wendy Brewster, MD, 1 Nisar Syed, MD, 2 Radiation Oncology, UC-Irvine, Orange, CA; 3 Obstetrics & Gynecology, UC-Irvine, Orange, CA.

P-35
HDR BRACHYTHERAPY, EXTENDED FIELD IRRADIATION AND CONCURRENT CHEMOTHERAPY IN STAGE IIB CERVICAL CARCINOMA
Ernest C Hymel, MD, PhD, 1 Mahesh A Varia, MD, 1 Linda Van Le, MD, 2 Paola A Gehrig, MD, 2 John F Boggess, MD, 2 Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; 2 Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC.

P-36
ADJUVANT RADIOTHERAPY FOR EARLY STAGE ENDOMETRIAL ADENOCARCINOMA
O Kenneth Macdonald, MD, 1 William T Sause, MD, 3 R Jeffery Lee, MD, 2 David K Gaffney, MD, PhD, 1 Radiation Oncology, Huntsman Cancer Hospital at the University of Utah, Salt Lake City, UT; 2 Radiation Oncology, Latter-Day Saint Hospital, Salt Lake City, UT.

P-37
BRACHYTHERAPY ALONE FOR INTERMEDIATE RISK ENDOMETRIAL CANCER
Lilie L Lin, MD, 1 Imran Zoberi, MD, 1 David Mutch, MD, 2 Perry W Grigsby, MD, MBA, 1 1 Radiation Oncology, Washington University in St. Louis, Saint Louis, MO; 2 Gynecologic Oncology, Washington University in St. Louis, St. Louis, MO.
P-38
IMAGE GUIDED HIGH-DOSE RATE INTERSTITIAL BRACHYTHERAPY (HDRB) FOR
GYNECOLOGICAL MALIGNANCIES
Ajay K Bhatnagar, MD, 1 Sushil Beriwal, MD, 1 Dwight E Heron, MD, 1 Raj S Selvaraj, MS, 1 Robert Mogus, MS, 1
Kristina Gerszten, MD, 1 John Comerci, MD, 1, 2 Radiation Oncology, University of Institute, Pittsburgh
Pittsburgh Cancer Institute, Pittsburgh, PA; 2 Gynecology Oncology, University of Pittsburgh Cancer, PA.

**Breast**

P-39
ACUTE TOXICITY ANALYSIS OF BREAST CANCER PATIENTS TREATED WITH ACCELERATED
PARTIAL BREAST IRRADIATION (APBI) USING MAMMOSITE COMPARING A 2-DAY VS 5-DAY
DOSE SCHEDULE
Michelle F Wallace, RN, BSN, OCN, 1 Alvaro A Martinez, MD, 1 Peter Y Chen, MD, 1 Michel I Ghilezan, MD, 1
Pamela Benitez, MD, 1 Nancy A Dunn, RN, BS, OCN, 1 Kimberly K Isler, RN, MSN, OCN, 1 Frank A Vicini, MD, 1
1 Radiation Oncology, William Beaumont Hospital, Royal Oak, MI; 2 Department of Surgical Services, William
Beaumont Hospital, Royal Oak, MI.

P-40
TECHNICAL FACTORS AFFECTING EARLY TOXICITY AND COSMETIC OUTCOME FOLLOWING
MAMMOSITE BRACHYTHERAPY- THE WILLIAM BEAUMONT HOSPITAL EXPERIENCE
Yasmin Hasan, M.D., 1 Frank A Vicini, M.D., F.A.C.R., 1 Peter Y Chen, M.D., 1 Pamela Benitez, M.D., 1 Larry L Kestin,
M.D., 1 Michelle Wallace, R.N., 1 Jane Pettinga, M.D., 2 Dwight L Fitch, M.D., 1 Alvaro A Martinez, M.D., F.A.C.R. 1
1 Radiation Oncology, William Beaumont Hospital, Royal Oak, MI; 2 Department of Surgery, William Beaumont
Hospital, Royal Oak, MI.

P-41
PERFORMANCE OF AN ELECTRONIC BRACHYTHERAPY SYSTEM FOR ACCELERATED PARTIAL
BREAST IRRADIATION IN A GOAT MAMMARY MODEL
John W Rieke, MD, 1 Darius S Francescatti, MD, 2 Mark J Rivard, PhD, 1 Jacqueline P Williams, PhD, 1 Steve Axelrod,
PhD, 1 Robert R Burnside, MS, 1 Eric W Chell, PhD, 5 Steven D Hansen, MS, 5 Thomas W Rusch, PhD, 5 Daren L
Stewart, 5 1 Radiation Oncology, Puget Sound VAHCS, Seattle, WA; 2 Surgery, Rush Medical School, Chicago, IL;
3 Radiation Oncology, Tufts-New England Medical Center, Boston, MA; 4 Radiation Oncology, University of Rochester
Medical Center, Rochester, NY; 5 Xoft, Inc., Fremont, CA.

P-42
SERIAL COMPUTED TOMOGRAPHIC ASSESSMENT OF MAMMOSITE BALLOON-CAVITY
CONFORMITY AND TREATMENT IMPLICATIONS
Michael A Papagikos, M.D., 1 Amanda R Havnen, B.S., 2 Michael V Lawrence, B.S., 2 Mahta Mirzaei, M.S., 1 Carolyn
R Ferree, M.D., 1 1 Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC;
2 Biomedical Engineering, Wake Forest University, Winston-Salem, NC.

P-44
QUALITY OF LIFE IN PATIENTS DURING AND AFTER MAMMOSITE BRACHYTHERAPY
Alice F Tsai, M.D., 1 Dattareyudu Nori, M.D., 1 Mary K Hayes, M.D. 1 1 Radiation-Oncology, New York Hospital Weill-
Cornell Medical Center, New York, NY.

P-45
INVESTIGATION OF SKIN DOSE REDUCTION IN MAMMOSITE® HDR BRACHYTHERAPY USING A
MODIFIED, ROTATING APPLICATOR DESIGN
Amir G Sadeghi, PhD, 1, 2 Bradley R Prestidge, MD, 1, 2 Scott Winter, BS, 2 Arthur Rosenthal, MD, 1 1 Radiation
Oncology, Texas Cancer Clinic, San Antonio, TX; 2 Radiological Sciences, University of Texas Health Science Center
at San Antonio, San Antonio, TX; 3 Surgery, Southwest Texas Methodist Hospital, San Antonio, TX.
P-46
CONTRALATERAL BREAST DOSE: A PHANTOM STUDY OF ACCELERATED INTRACAVITARY PARTIAL BREAST IRRADIATION AND THE EFFECT OF MIDLINE EXTERNAL LEAD SHIELDING
Alexandra J Stewart, BM, MRCP, Jorgen L Hansen, MSc, Desmond A O’Farrell, CMD, Robert A Cormack, PhD, Jennifer R Bellon, MD, Subhakar Mutyala, MD, Phillip M Devlin, MD. Radiation Oncology, Brigham and Women’s Hospital, Dana Faber Cancer Institute, Boston, MA.

P-47
ACCELERATED INTRACAVITARY PARTIAL BREAST IRRADIATION TO THE LEFT BREAST: A WHOLE HEART DOSE VOLUME HISTOGRAM ANALYSIS
Alexandra J Stewart, BM, MRCP, Desmond A O’Farrell, CMD, Jorgen L Hansen, MSc, Robert A Cormack, PhD, Jennifer R Bellon, MD, Subhakar Mutyala, MD, Phillip M Devlin, MD. Radiation Oncology, Brigham and Women’s Hospital, Dana Faber Cancer Institute, Boston, MA.

P-49
CHEST WALL DOSE IN MAMMOSITE BREAST BRACHYTHERAPY: RADIOBIOLOGIC ESTIMATIONS OF LATE COMPLICATION RISK BASED ON DOSE-VOLUME CONSIDERATIONS
Anthony E Dragun, MD, Joseph M Jenrette, MD, Eric G Aguero, MD, Joseph F Harmon, PhD, Jennifer L Harper, MD. Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC.

P-50
POST-SURGICAL PLACEMENT OF MAMMOSITE® APPLICATOR USING THE PINPOINT™ CT SCANNER INTEGRATED STEREOTACTIC ARM
Gene A Cardarelli, MS, MPH, Jen-San Tsai, PhD, Jess Hiatt, BS, Thomas DiPetrillo, MD, Melissa Remis, MD, Muhammed Y Puthawala, MD, Carla Bradford, PHD, David Wazer, MD. Radiation Oncology, Rhode Island Hospital, Providence, RI; Radiation Oncology, Brown University School of Medicine, Providence, RI.

Head and Neck

P-51
TOLERANCE OF CERVICAL SPINAL CORD TO HDR BRACHYTHERAPY AND EXTERNAL BEAM RADIATION IN TREATMENT OF HEAD AND NECK CANCERS
Bhupesh Parashar, MD, Ravindra Yaparpalvi, MS, Madhur Garg, MD, Shalom Kalnicki, MD, Jonathan J Beitler, MD, MBA, FACR. Radiation Oncology, Montefiore Medical Center, Bronx, NY.

P-52
EXPERIENCE WITH HIGH DOSE RATE (HDR) BRACHYTHERAPY IN THE TREATMENT OF TUMORS OF THE BASE OF TONGUE
Zoltan Takaci-Nagy, MD, Ferenc Oberna, MD, Csaba Polgar, MD PhD, Tibor Major, PhD, Janos Fodor, DSc. Department of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oral Surgery, St.Rokus Hospital, Budapest, Hungary.

P-53
HDR INTERSTITIAL BRACHYTHERAPY IN RECURRENT AND PREVIOUSLY IRRADIATED HEAD AND NECK CANCERS – PRELIMINARY RESULTS
Ashwatha Narayana, MD, Gilad Cohen, PhD, Marco Zaider, PhD, Jatin Shah, MD, Ashok Shaha, MD, Dennis Kraus, MD, Michael Zelefsky, MD. Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY; Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
P-54
IRIDIUM-192 INTERSTITIAL BRACHYTHERAPY FOR SQUAMOUS CARCINOMA OF THE ORAL TONGUE
Ying Hitchcock, Jergin Chen, Pramod Sharma, Jonh Moeller, David Gaffney, Jim Rankin, Dennis Shrieve, .
Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Otolaryngology-Head and Neck Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

P-55
A CASE STUDY OF NASOPHARYNGEAL CARCINOMA THAT PROGRESSSED IN THE CLIVUS WHILE RECEIVING EXTERNAL BEAM RADIATION CONCURRENTLY WITH CHEMOTHERAPY AND WAS SALVAGED SUCCESSFULLY WITH INTERSTITIAL HIGH DOSE RATE (HDR) BRACHYTHERAPY TO THE CLIVUS AND NASOPHARYNX
A Akl, M.D., J Shah, M.D. FRCS(C), S Zafiroff, MS, I Abdulhay, Ph.D., L Boulay, M.S., A Ismail, Ph.D., N Ahmad, M.D., M Agabigum, M.D., R Mikhail, M.D. Radiation Oncology, Genesys Hurley Cancer Institute, Flint, MI.

P-56
RESULTS OF INTERSTITIAL HDR HIGH DOSE RATE BRACHYTHERAPY IN TREATMENT OF EARLY (T1T2) TONGUE CANCER
A Akl, M.D., S Zafiroff, MS, I Abdulhay, Ph.D., A Ismail, Ph.D., L Boulay, M.S., N Ahmad, M.D., M Agabigum, M.D., S Marchetta, D.O., R Mikhail, M.D., S Mukkamala, M.D., W Robins, D.O., K Shukairy, M.D., M Ulrich, D.O. Radiation Oncology, Genesys Hurley Cancer Institute, Flint, MI.

P-57
VALIDATION MEASUREMENTS OF DOSE DELIVERED FROM A NOVEL ELECTRONIC BRACHYTHERAPY X-RAY SOURCE
Steve Axelrod, PhD, Earl E Dozier, Thomas W Rusch, PhD, R&D, Xoft, Inc., Fremont, CA.

P-58
COMPARISON OF CHEST RADIOGRAPHS, FLUOROSCOPY AND SEED-MIGRATION DETECTOR FOR THE DETECTION OF EMBOLIZED SEEDS TO THE LUNG
Janelle Morrier, MSc, Mario Chretien, MSc, Luc Beaulieu, PhD, Radiation Oncology and Centre de Recherche en Cancérologie, CHUQ, Quebec, QC, Canada.

P-59
TG-43U1 BASED DOSIMETRIC CHARACTERIZATION OF MODEL 67-6520 CS-137 BRACHYTHERAPY SOURCE
Ali S Meigooni, Ph.D, Clarissa Wright, B.S., Rebecca F Duncan, M.S., Venkata Rachababathula, M.S., Rafiq A Koona, M.S., Curtis H Baker, B.S. Radiation Medicine, University of Kentucky, Lexington, KY.

P-60
FIRST RESULTS OF THE EQUAL-ESTRO-BRAPHYQS AUDITS FOR BRACHYTHERAPY, GEOMETRIC RECONSTRUCTION TECHNIQUES AND Ir-192 HDR DOSE DELIVERY
Amelie Roue, Jack Venselaar, Ph.D, Jan Van Dam, PhD, Hans Svensson, PhD, EQUAL-ESTRO Laboratory, ESTRO, Villejuif, France, Radiotherapy Department, Dr. B. Verbeeten Instituut, Tilburg, Netherlands, Radiation Physics Department, University of Umea, Umea, Sweden.

P-61
MIXED-FIELD DOSIMETRY FOR A HDR Cf-252 BRACHYTHERAPY SOURCE
Christopher S Melhus, M.Sc., Mark J Rivard, Ph.D. Radiation Oncology, Tufts-New England Medical Center, Boston, MA.
P-62
RADIATION PROTECTION DATA OF NEW BRACHYTHERAPY SOURCES
Jack Venselaar, PhD,1 Jose Perez-Calatayud, PhD,2 Facundo Ballester, PhD,3 Adrie Bos, PhD,2 D Granero, PhD,3
1 Radiotherapy Department, Dr. B. Verbeeten Instituut, Tilburg, Netherlands; 2 Radiotherapy Department, La Fe Hospital, Valencia, Spain; 3 Department of Atomic, Molecular and Nuclear Physics, University of Valencia and IFIC-CSIC, Burjassot, Spain; 4 Faculty of Applied Physics, Delft University of Technology, Delft, Netherlands.

P-63
RADIOCHROMIC FILM DOSIMETRY FOR I-125 SEED IN SOLID WATER
Sou-Tung Chiu-Tsao, PhD,1 Yunsil Ho, PhD,1 Daniel Shasha, MD,1 Louis B Harrison, MD,1 1 Radiation Oncology, Beth Israel Medical Center & St. Luke’s Roosevelt Hospital Center, New York, NY.

P-65
ERROR ANALYSIS IN MONTE CARLO SIMULATION OF LOW ENERGY BRACHYTHERAPY SOURCES
Rafiq A Koona, M.S.,1 Venkata Rachabathula, M.S.,2 Shahid B Awan, M.S.,2 William R Dieter, Ph.D.,1 Ali S Meigooni, Ph.D.,1 1 Department of Electrical and Computer Engineering, University of Kentucky, Lexington, KY; 2 Department of Radiation Medicine, University of Kentucky, Lexington, KY.

P-66
MOSFET AS IN VIVO DOSIMETERS FOR PROSTATE HDR REAL-TIME QUALITY ASSURANCE
Christine Tremblay, M.Sc.,1,2 Luc Gingras, Ph.D.,1,2 Louis Archambault, M.Sc.,1,2 Mario Chretien, M.Sc.,1 Andre-Guy Martin, M.D., M.Sc.,1 Rene Roy, Ph.D.,2 Luc Beaulieu, Ph.D.1,2 1 Département de radio-oncologie, Centre Universitaire de Québec, Pavillon de l’Hôtel-Dieu de Québec, Québec, QC, Canada; 2 Département de Physique, Génie Physique et Optique, Université Laval, Québec, QC, Canada.

P-67
CONE BEAM CT BASED PLANNING FOR HIGH AND LOW DOSE RATE BRACHYTHERAPY
Amir G Sadeghi, PhD,1,2 Bradley R Prestidge, MD,1,2 Sylvia G Zubyk, MD,1 William S Bice, PhD,1,2 1 Radiation Oncology, Texas Cancer Clinic, San Antonio, TX; 2 Radiological Sciences, University of Texas Health Science Center at San Antonio, San Antonio, TX.

P-68
DOSIMETRIC COMPARISON BETWEEN HIGH-DOSE-RATE INTERSTITIAL AND MAMMOSITE BALLOON BRACHYTHERAPY FOR BREAST CANCER
Tibor Major, PhD,1 Csaba Polgar, MD, PhD,1 Janos Fodor, MD, PhD, DSc,1 1 Radiotherapy Department, National Institute of Oncology, Budapest, Hungary.

P-69
IMPROVED CLINICAL OUTCOME WITH HIGH DOSE RADIATION: A PROSPECTIVE DOSE ESCALATION TRIAL USING HIGH DOSE RATE BRACHYTHERAPY BOOST
Thomas P Boike, B.S.,1 Carlos E Vargas, M.D.,1 Alvaro A Martinez, M.D., F.A.C.R.,1 Gregory Edmundson, M.S.,1 Peter Y Chen, M.D.,1 Gary S Gustafson, M.D.,1 Daniel J Krauss, M.D.1 1 Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.

P-70
PROGNOSTIC SIGNIFICANCE OF PERINEURAL INVASION FOLLOWING PROSTATE BRACHYTHERAPY
Gregory S Merrick, MD,1,4 Wayne M Butler, PHD,1,4 Kent E Wallner, MD,2 Robert W Galbreath, PHD,1,4 Zachariah A Allen, MS,1,4 Edward Adamovich, MD,1 1 Schiffer Cancer Center, Wheeling Hospital, Wheeling, WV; 2 Puget Sound Health Care System, University of Washington, Seattle, WA; 3 Pathology, Wheeling Hospital, Wheeling, WV; 4 Physics, Wheeling Jesuit University, Wheeling, WV.
P-71
DOSE CONSTRAINTS IN INVERSE PLANNING HDR PROSTATE BRACHYTHERAPY FOR THE DOSE ESCALATION OF DIL DEFINED BY MR SPECTROSCOPY IMAGING
Yongbok Kim, Ph.D.,1 I-Chow J Hsu, M.D.,1 Etienne Lessard, Ph.D.,1 John Kurhanewicz, Ph.D.,2 Susan Moyher Noworolski, Ph.D.,2 Jean Pouliot, Ph.D.,1 1Radiation Oncology, University of California, San Francisco, San Francisco, CA; 2Radiology, University of California, San Francisco, San Francisco, CA.

P-72
ESTABLISHING THE OPTIMAL BIOCHEMICAL FAILURE DEFINITION FOR PROSTATE BRACHYTHERAPY PATIENTS
Larry L Kestin, M.D.,1 Dwight Fitch, M.D.,1 Tom Boike,1 Courtney Byrd,1 Alvaro Martinez, M.D.,1 Frank Vicini, M.D.1 1Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.

P-73
RELATIONSHIP BETWEEN PREIMPLANT INTERNATIONAL PROSTATE SYMPTOM SCORE AND URINARY MORBIDITY FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY
Sarah Gutman,1 Gregory S Merrick, MD,1,2 Wayne M Butler, PhD,1,2 Kent E Wallner, MD,1 Zachariah A Allen, MS,1,2 Robert W Galbreath, PHD,1,2 1Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV; 2Physics, Wheeling Jesuit University, Wheeling, WV.

P-74
CLASS SOLUTION FOR INVERSLEY PLANNED PERMANENT PROSTATE IMPLANTS TO MIMIC AN EXPERIENCED DOSIMETRIST FOR PRE AND LIVE TREATMENT PLANNING
Etienne Lessard, Ph.D.,1 Stefan LS Kwa, Ph.D.,2 Barby Pickett, CMD,1 Mack Roach III, MD,1 Jean Pouliot, Ph.D.1 1Department of Radiation Oncology, UCSF Comprehensive Cancer Center, San Francisco, CA; 2Nucletron B.V., Veenendaal, Netherlands.

P-75
MRI BASED OBSERVATIONS OF ANATOMIC DISTORTIONS SECONDARY TO PERMANENT I-125 PROSTATE IMPLANTATION
Naoyuki G Saito, M.D., Ph.D.,1 Vrinda Narayana, Ph.D.,1,2 Sara A Troyer, B.S.,1,2 Sally M Berri, B.S.,1,2 Patrick W McLaughlin, M.D.,1,2 1Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; 2Department of Radiation Oncology, Providence Hospital, Southfield, MI.

P-76
A COMPARISON AT 10 YEARS OF HIGH DOSE RATE BRACHYTHERAPY AND EXTERNAL RADIATION WITH AND WITHOUT ANDROGEN SUPPRESSION FOR PROSTATE CANCER
D Jeffrey Demanes, M.D.,1 Gillian Altieri, C.M.D.,1 David Brandt, M.A.,1 Marie-Claire Barnaba, M.S.N-NP,1 Lionel Schour, M.D.,1 Pat Skoolisariyaporn, M.S.1,2 California Endocurietherapy Cancer Center, California Endocurietherapy Cancer Center, Oakland, CA.

P-77
DETAILED URETHRAL DOSIMETRY IN THE EVALUATION OF PROSTATE BRACHYTHERAPY-RELATED URINARY MORBIDITY
Zachariah A Allen, M.S.,1 Gregory S Merrick, M.D.,1 Wayne M Butler, PH.D.,1 Kent E Wallner, M.D.,1 Brian Kurko, B.S., C.M.D.,1 Richard L Anderson, B.S., C.M.D.,1 Brian C Murray, B.S.,1 Robert W Galbreath, PH.D.1 1Schiffler Cancer Center & Wheeling Jesuit University, Wheeling Hospital, Wheeling, WV.
P-78
PROSTATE VOLUME AND SEED LOCATION AS A FUNCTION OF THE DISTANCE TO THE RECTUM AND URETHRA: DESIGN CONSIDERATIONS FOR TRANS-URETHRAL ULTRASOUND DURING PROSTATE BRACHYTHERAPY
David R Holmes III, PhD,1 Brian J Davis, MD, PhD,2 Christopher C Goulet, MD,2 Michael G Herman, PhD,2 Lance A Mynderse, MD,3 Richard A Robb, PhD,3 1 Biomedical Imaging Resource, Mayo Clinic College of Medicine, Rochester, MN; 2 Division of Radiation Oncology, Mayo Clinic, Rochester, MN; 3 Department of Urology, Mayo Clinic, Rochester, MN.

P-79
EFFECT OF POST-IMPLANT EDEMA ON TREATMENT MARGIN MEASUREMENTS AFTER PROSTATE BRACHYTHERAPY WITH MRI-BASED DOSIMETRY
Dainel R Reed, DO,1,2 Kent E Wallner, MD,1,2 Eric Ford, PhD,1,2 Gregory Merrick, MD,3 Wayne Butler, PhD,3 Sreeram Narayanan, PhD,1,2 Paul Cho, PhD,1,2 1 Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA; 2 Radiation Oncology, University of Washington Medical Center, Seattle, WA; 3 Radiation Oncology, Schiffler Cancer Center, Wheeling, WV.

P-80
RELATIONSHIP BETWEEN ISOTOPE, PROSTATE VOLUME AND URINARY MORBIDITY FOLLOWING PROSTATE BRACHYTHERAPY
Angela Niehaus,1 Gregory S Merrick, MD,1,2 Wayne M Butler, PhD,1,2 Kent E Wallner, MD,1 Zachariah A Allen, MS,1,2 Robert W Galbreath, PHD,1,2 Edward Adamovich, MD,3 Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV; 2Physics, Wheeling Jesuit University, Wheeling, WV; 3Pathology, Wheeling Hospital, Wheeling, WV.

P-81
IDENTIFICATION OF THE OPTIMAL DOSE FOR HDR BOOST BRACHYTHERAPY BASED ON CLINICAL FAILURES AND MULTIPLE BIOCHEMICAL DEFINITIONS
Carlos Vargas, MD,1 Alvaro Martinez, MD,1 Thomas Boike,1 Gregory Edmundson, MD,1 Gary Gustafson, MD,1 Daniel Krauss, MD,1 Peter Chen, MD,1 Courtney Byrd,1 Larry Kestin, MD,1 1Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.

P-83
RECTAL TOXICITY AFTER I 125 PERMANENT PROSTATE IMPLANTS IN 445 PATIENTS: IS RECTAL AND PROSTATE DOSIMETRY RELATED TO TOXICITY?
Mira Keyes, MD FRCPC,1 Veronika Moravan, M.Sc,2 Mitchell Liu, MDCM,3 Bojana Jankovic, M.Sc,4 James Morris, MD FRCPC,1 1 Radiation Oncology, Vancouver Cancer Centre,British Columbia Cancer Agency, Vancouver, BC, Canada; 2 Radiation Oncology, Fraser Valley Cancer Centre, British Columbia Cancer Agency, Surry, BC, Canada; 3 Population and Preventive Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; 4 BC Cancer Research Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.

P-84
RELATIONSHIP BETWEEN POST-VOID RESIDUAL URINE AND BRACHYTHERAPY-RELATED URINARY MORBIDITY
Megan Beekman, B.S.,1 Gregory S Merrick, M.D.,1 Wayne M Butler, PH.D,1 Kent E Wallner, M.D.,1 Zachariah A Allen, M.S.,1 Sarah Gutman,1 Jacqueline Usher, B.S.,1 Robert W Galbreath, PH.D,1 Schiffler Cancer Center & Wheeling Jesuit University, Wheeling Hospital, Wheeling, WV.

P-85
BYPASSING THE LEARNING CURVE IN PERMANENT SEED IMPLANTS USING STATE-OF-THE-ART TECHNOLOGY
Luc Beaulieu, PhD,1 Dee-Ann Radford, MSc,2 Sylviane Aubin, MSc,1 S Angyalfli, MD,2 Siraj Husain, MD,2 Ian Kay, PhD,2 Andre-Guy Martin, MD, MSc,1 Nicolas Varfalvy, MSc,1 Eric Vigneault, MD, Msc,1 Peter Dunscombe, PhD,2 1Radiation Therapy, Centre Hospitalier Universitaire de Québec, Québec, QC, Canada; 2Radiation Therapy, Tom Baker Cancer Centre, Calgary, AB, Canada.
P-86
HIGH DOSE RATE (HDR) PROSTATE BOOST IMPLANT: COMPARISON OF ACUTE AND CHRONIC TOXICITIES BETWEEN THREE DOSE ESCALATION GROUPS
Grace A Boyea, RN, BSN,1 Michelle F Wallace, RN, BSN, OCN,1 Peter Y Chen, MD,1 Gary S Gustafson, MD,1 Alvaro A Martinez, MD,1 Linda Lewis, RN, BSN,1 Christine Flynn, RN, BSN,1 Anita Axiak, RN, BSN.1 2 Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.

P-87
INCIDENCE OF LATE RECTAL MORBIDITY FOLLOWING BRACHYTHERAPY WITH OR WITHOUT CONFORMAL EXTERNAL BEAM RADIATION THERAPY
Nicolas K Kuritzky, MD,1 Robert M Allbright, MD,1 Albert Sabbas, PhD,1 Samuel Trichter, MS,1 Dattatreyudu Nori, MD.1 1 Radiation Oncology, New York Presbyterian Hospital-Weill Cornell Medical Center, New York Hospital, NY.

P-88
SEVEN YEAR BIOCHEMICAL DISEASE FREE SURVIVAL RATES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY WITH DOSE ESCALATION TO BIOLOGICAL TUMOR VOLUMES (BTVs) IDENTIFIED WITH SPECT/CT IMAGE FUSION
Rodney J Ellis, M.D.,1 Edward Kim, M.D.,2 Hang Zhou, M.D.,1 Pingfu Fu, Ph.D.,3 Valdir Colussi, Ph.D.,2 Bruce Sodee, M.D.,4 Patrick Spirnak, M.D.,1 Kurt Dinchman, M.D.,1 Martin I Resnick, M.D.3 1 Urology, Case Western Reserve University, Cleveland, OH; 2 Radiation Oncology, Case Western Reserve University, Cleveland, OH; 3 Bio-Statistics, Case Western Reserve University, Cleveland, OH.

P-89
THE IMPACT OF PRIMARY GLEASON GRADE ON BIOCHEMICAL OUTCOME FOLLOWING BRACHYTHERAPY FOR HORMONE NAÏVE GLEASON SCORE 7 PROSTATE CANCER
Gregory S Merrick, M.D.,1 Wayne M Butler, PH.D.,1 Kent E Wallner, M.D.,1 Robert W Galbreath, PH.D.,1 Zachariah A Allen, M.S.,1 Edward Adamovich, M.D.1 1 Schiffler Cancer Center & Wheeling Jesuit University, Wheeling Hospital, Wheeling, WV.

P-90
HIGH DOSE RATE MONOTHERAPY FOR PROSTATE CANCER: CET’S 5 YEAR RESULTS
D Jeffrey Demanes, M.D.,1 Gillian Altieri, C.M.D.,2 David Brandt, M.A.,1 Marie-Claire Barnaba, M.S.N.-NP,1 Pat Skoolisariyaporn, M.S.,1 Lionel Schour, M.D.1 1 California Endocurietherapy Cancer Center, California Endocurietherapy Cancer Center, Oakland, CA.

P-91
RECTAL MORBIDITY FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY WITH DOSE ESCALATION TO BIOLOGICAL TUMOR VOLUMES (BTVs) IDENTIFIED WITH SPECT/CT IMAGE FUSION
Rodney J Ellis, M.D.,1 Edward Kim, M.D.,2 Hang Zhou, M.D.,1 Pingfu Fu, Ph.D.,3 Valdir Colussi, Ph.D.,2 Bruce Sodee, M.D.,4 Patrick Spirnak, M.D.,1 Kurt Dinchman, M.D.,1 Martin I Resnick, M.D.3 1 Urology, Case Western Reserve University, Cleveland, OH; 2 Radiation Oncology, Case Western Reserve University, Cleveland, OH; 3 Bio-Statistics, Case Western Reserve University, Cleveland, OH.

P-92
PERMANENT PROSTATE BRACHYTHERAPY I-125 IMPLANTS WITH MORE SEEDS RESULT IN PROSTATE DOSE VOLUME STATISTICS LESS SENSITIVE TO UNCERTAINTY IN SEED PLACEMENT: AN EXTENSIVE SIMULATION STUDY OF NINE CASES
Yi Su, B.S.,1 Brian J Davis, M.D., Ph.D.,2 Michael G Herman, Ph.D.,2 Armando Manduca, Ph.D.,3 Richard A Robb, Ph.D.1 1 Biomedical Imaging Resource, Mayo Clinic and Foundation, Rochester, MN; 2 Division of Radiation Oncology, Mayo Clinic and Foundation, Rochester, MN; 3 Biomathematics Resource, Mayo Clinic and Foundation, Rochester, MN.
26TH ANNUAL MEETING

P-93
EARLY CLINICAL OUTCOME WITH TWO YEARS BIOPSY RESULTS OF HDR PROSTATE BOOST USING INVERSE PLANNING: THE QUEBEC EXPERIENCE
Eric Vigneault, MD, MSc,1 Luc Beaulieu, PhD,1 Francois Harel, MSc,1 Bernard Lachance, MSc,1 Etienne Lessard, PhD,2 Jean Pouliot, PhD,2 Andre-Guy Martin, MD, Msc,1,2 Radiation Therapy, Centre Hospitalier Universitaire de Québec, Québec, QC, Canada; 2 Radiation Oncology, UC San Francisco, San Francisco, CA.

P-95
IMPACT OF URETHRAL CATHETER AND LEG POSITIONING ON IN VIVO DOSIMETRY IN PATIENTS UNDERGOING 1125 SEED IMPLANTATION
William Foster, MD,1 Sylviane Aubin, MSc, Luc Beaulieu, PhD, Andre-Guy Martin, MD, Eric Vigneault, MD.
1 Département de radio-oncologie, L’Hôpital-Dieu de Québec, CHUQ, Québec, QC, Canada.

P-96
INCIDENCE AND CHANGE OVER TIME OF ADVERSE ISODOSE PATTERNS IN PATIENTS UNDERGOING PROSTATE BRACHYTHERAPY
Daniel R Reed, D.O.,1,2 Kent E Wallner, M.D.,1,2 Eric Ford, PhD,1,2 Sreeram Narayanan, PhD,1,2 Gregory Merrick, M.D.,1 Peter Orio, D.O.,1,2 Paul Cho, PhD,1,2 Radiation Oncology, University of Washington Medical Center, Seattle, WA; 2 Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA;
3 Radiation Oncology, Schiffler Cancer Center, Wheeling, WV.

P-97
HIGH DOSE RATE BRACHYTHERAPY OF LARGE VOLUME PROSTATE
Alvin Korba, M.D.,1 Aly Razek, M.D.,1 Saiyid M Shah, Ph.D.,1 Paul Siami, M.D.,1 Barbara Smith, RN, BSN, OCN,1 Arnold Sorensen, B.S.,1 William C Fisher, M.D.,1 Douglas Foertsch, M.D.,1 Thomas Gadient, M.D.,1 Phillip M Gilson, M.D.,1 Bruce W Romick, M.D.,1 Bill J Samm, M.D.1,2 Tri-State Prostate Cancer Center, Tri-State Prostate Cancer Center/Evansville Cancer Center, Evansville, IN.

P-98
GEOMETRICAL CHARACTERIZATION OF THE PROSTATIC URETHRA FROM CT DATA FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY: APPLICATIONS TO TRANS-URETHRAL IMAGING AND BRACHYTHERAPY PLANNING
Christopher C Goulet, MD,1 David R Holmes III, PhD,2 Keith M Furutani, PhD,1 Michael G Herman, PhD,1 Torrence M Wilson, MD,1 Richard A Robb, PhD,2 Brian J Davis, MD, PhD,1 1 Division of Radiation Oncology, Mayo Clinic, Rochester, MN; 2 Biomedical Imaging Resource, Mayo Clinic, Rochester, MN; 3 Department of Urology, Mayo Clinic, Rochester, MN.

P-99
A COMPARISON OF PROSTATE DIMENSIONS AND VOLUME IN PATIENTS UNDERGOING RADICAL RETROPUBIC PROSTATECTOMY, EXTERNAL BEAM RADIATION THERAPY, OR PERMANENT PROSTATE BRACHYTHERAPY FOR LOCALIZED ADENOCARCINOMA
James L Leenstra, M.D.,1 Brian J Davis, M.D., Ph.D.,2 David W Hillman, M.S.,2 Katie L Allen, B.S.,2 John C Cheville, M.D.,4 Michael G Herman, Ph.D.,2 Torrence M Wilson, M.D.,2 Lance A Mynderse, M.D.,3 Bernard F King, M.D.4:1 Department of Internal Medicine, Mayo Clinic, Rochester, MN; 2 Division of Radiation Oncology, Mayo Clinic, Rochester, MN; 3 Department of Biostatistics, Mayo Clinic, Rochester, MN; 4 Department of Pathology, Mayo Clinic, Rochester, MN; 5 Department of Urology, Mayo Clinic, Rochester, MN; 6 Department of Radiology, Mayo Clinic, Rochester, MN.
P-100
EARLY OUTCOME AND DOSIMETRY OF LOW AND INTERMEDIATE RISK PROSTATE CANCER PATIENTS TREATED WITH IODINE 125 FLUOROSCOPIC AND ULTRASOUND GUIDED PERMANENT BRACHYTHERAPY
Brian J Davis, MD, PhD,1 Torrence M Wilson, MD,2 Lance A Mynderse, MD,2 Jeffrey M Slezak, BS,3 Erik A Bergstralh, BS,3 Bernard F King, MD,4 Wayne N LaJoie, CMD, BS,1 Michael G Herman, PhD,1 Division of Radiation Oncology, Mayo Clinic, Rochester, MN; 2 Department of Urology, Mayo Clinic, Rochester, MN; 3 Department of Biostatistics, Mayo Clinic, Rochester, MN; 4 Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN.

P-101
FACTORS PREDICTING FOR ACUTE URINARY MORBIDITY FOLLOWING PERMANENT 125I IMPLANTATION OF THE PROSTATE: INSIGHTS FROM A POOLED ANALYSIS OF TWO PROSPECTIVE, RANDOMIZED TRIALS
Vipul V Thakkar, MD,1 Mohamed Elshaikh, MD,2 Thomas Carlson, MD,3 Chandana A Reddy, MS,1 Kenneth Angermeier, MD,4 Eric A Klein, MD,4 James Ulchaker, MD,4 Andrew Altman, MD,5 Jay P Ciezki, MD,1 1Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH; 2 Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; 3 Department of Radiation Oncology, Ben Taubs Cancer Center, Houston, TX; 4 The Glickman Urologic Institute, Cleveland Clinic Foundation, Cleveland, OH; 5 Department of Urology, Kaiser Permanente, Cleveland, OH.

P-102
NUMBER OF CATHETERS, POSITION INSERTION UNCERTAINTY AND OPTIMUM DISTRIBUTION IN HDR BRACHYTHERAPY USING INVERSE PLANNING
Jean Pouliot, Ph.D.,1 Etienne Lessard, Ph.D.,1 Luc Beaulieu, Ph.D.,2 I-Chow Hsu, MD,1 1Department of Radiation Oncology, UCSF Comprehensive Cancer Center, San Francisco, CA; 2 Department de Radio-oncologie, Centre Hospitalier Universitaire de Quebec, Quebec City, QC, Canada.

P-103
URETHRAL SPECTROSCOPIC ALARM (USA) PROBE FOR PROSTATE IMPLANTS
Anatoly B Rosenfeld, PhD,1 Dean L Cutajar, MSc,2 Michael LF Lerch, PhD,1 George J Takach, PhD,1 Joseph A Bucci, MD,2 Lisa J Duggan, PhD,2 Marco Zaider, PhD,2 Michael Zelefsky, MD,2,3 Gilad N Cohen, MSc,1 1Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia; 2 Institute for Prostate Cancer, St. George Cancer Care Centre, Kogarah, Australia; 3 Department of Medical Physics, MSKCC, New York, NY; 4 Department of Radiation Oncology, MSKCC, New York, NY.

P-104
DOSIMETRIC COMPARISON OF INTRA-OPERATIVE AND PRE-PLANNING TECHNIQUES FOR 3D ULTRASOUND IMAGE GUIDED PERMANENT SEED PROSTATE BRACHYTHERAPY
Dee-Ann Radford Evans, MSc,1 Steve Angyalfi, MD,2,3 Siraj Husain, MD,2,3 Ian Kay, PhD,1,3 Peter Dunscombe, PhD,1,3 1Department of Medical Physics, Tom Baker Cancer Centre, Calgary, AB, Canada; 2 Department of Radiation Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada; 3 Department of Oncology, University of Calgary, Calgary, AB, Canada.

P-106
A QUALITY OF LIFE (QOL) ASSESSMENT OF PROSTATE CANCER PATIENTS UNDERGOING DIFFERENT RADIATION TREATMENT MODALITIES
Kathleen A Saputo, RN, BSN,1 Kimberly K Isler, RN, MSN, OCN,1 Michelle F Wallace, RN, BSN, OCN,1 Grace A Boyea, RN, BSN,1 Christine J Flynn, RN, BSN,1 Mamtha Balasubramaniam, MS,2 Alvaro A Martinez, MD,1 1Radiation Oncology, William Beaumont Hospital, Royal Oak, MI; 2 Division of Biostatistics, Research Institute, William Beaumont Hospital, Royal Oak, MI.
P-107
EFFICACY OF NEOADJUVANT DUTASTERIDE AND BICALUTAMIDE AS A CYTOTOCH REDUCTIVE REGIMEN PRIOR TO PERMANENT INTERSTITIAL BRACHYTHERAPY
Gregory S Merrick, MD,1,2 Wayne M Butler, PHD,1,2 Kent E Wallner, MD,1 Robert W Galbreath, PHD,1,2 Robert Coram, R.Ph., MBA,1,2 Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV; 2 Physics, Wheeling Jesuit University, Wheeling, WV; 1 Puget Sound Health Care Corporation, University of Washington, Seattle, WA.

P-108
RAPID STRAND™ VS. LOOSE (IODINE-125 SEEDS): A PROSPECTIVE RANDOMIZED TRIAL
Daniel R Reed, DO,1 Kent E Wallner, MD,1,2 Amy Mueller, MD,2 Eric Ford, PhD,1,2 Steve Sutlief, PhD,2 Greg Merrick, MD,1 Paul Cho, PhD,1 Radiation Oncology, University of Washington, Seattle, WA; 2 Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA; ¹ Radiation Oncology, Schiffler Cancer Center, Wheeling, WV.

P-109
LDR vs. HDR BRACHYTHERAPY FOR GLEASON 7 ADENOCARCINOMA OF THE PROSTATE
Theodore CM Lo, M.D.,1 Patricia L Cronin,1 Robert A Roth, M.D,2 ¹ Radiation Oncology, Lahey Clinic Medical Center, Burlington, MA; 2 Urology, Lahey Clinic Medical Center, Burlington, MA.

P-110
SALVAGE HDR PROSTATE BRACHYTHERAPY FOR LOCAL RECURRENCE AFTER RADIOTHERAPY
I-Chow J Hsu, MD,1 Katsuto Shinohara, MD,2 Vivian Weinberg, Ph.D.,¹ Alexander R Gottschalk, MD,1 Jean Pouliot, Ph.D.,1 Mack Roach, MD,1 Radiation Oncology, University of California San Francisco, San Francisco, CA; 2 Urology, University of California San Francisco, San Francisco, CA.

P-111
PROSTATE MR SPECTROSCOPY IMAGE REGISTRATION USING BIOMECHANICAL MODELING OF TISSUE DEFORMATIONS DUE TO ENDORECTAL PROBE INSERTION
Ron Alterovitz, M.S.,1 Yongbok Kim, Ph.D.,2 John Kurhanewicz, Ph.D.,¹ Jean Pouliot, Ph.D.,2 I-Chow Hsu, M.D.,2 Ken Goldberg, Ph.D,¹ Department of Industrial Engineering and Operations Research, University of California, Berkeley, Berkeley, CA; 2 Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA; ¹ Magnetic Resonance Science Center, University of California, San Francisco, San Francisco, CA; 2 Departments of IEOR and EECS, University of California, Berkeley, Berkeley, CA.

P-112
BETTER ACUTE AND LATE GU TOXICITY PROFILE INCLUDING ERECTILE DYSFUNCTION (ED) WITH HDR BRACHYTHERAPY COMPARED WITH PIN103 SEEDS IMPLANT BASED ON CLINICAL DATA AND QUALITY OF LIFE (QOL) ASSESSMENT IN EARLY PROSTATE CANCER PATIENTS
Michel Ghilezan,1 Gary Gustafson,1 Carlos Vargas,1 Kimberly Isler,1 Mamtha Balasubramaniam,1 Michelle Wallace,1 Alvaro Martinez,1 Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.

P-113
CLINICAL EFFICACY OF COMPUTER OPTIMIZED THREE DIMENSIONAL HIGH DOSE RATE PROSTATE BRACHYTHERAPY
Yoshiya Yamada, MD, FRCPC,¹ Sudershan Bhatia, MD,¹ Gilad Cohen, MS,2 Marco Zaider, PhD,2 James Eastham, MD,3 Sherri M Donat, MD,1 Farhang Rabbani, MD,¹ Michael J Zelefsky, MD,1,2 Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; 2 Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY; 3 Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

P-114
TECHNIQUES IN REDUCTION OF SEED MIGRATION AFTER PROSTATE PERMANENT BRACHYTHERAPY
Qin-Sheng Chen, Ph.D.,1 Henry F Blair, M.D,¹ Radiation Oncology, Cleveland Clinic Foundation, Mayfield Heights, OH.
P-115
COMBINED HYPOFRACTIONATED HIGH DOSE RATE BRACHYTHERAPY (HDRBT) AND 3D EXTERNAL BEAM RADIOTHERAPY IN PATIENTS WITH INTERMEDIATE RISK PROSTATE CANCER
Marie Duclos, Radiation Oncologist, Armen Aprikian, Urologist, Micheal Evans, Medical Physicist, Fabio Curry, Fellow, Marc David, Radiation Oncologist, Sergio Faria, Radiation Oncologist, Georges Shenouda, Radiation Oncologist, Luis Souhami, Radiation Oncologist. 1Radiation Oncology, McGill University, Montreal, QC, Canada; 2Urology, McGill University, Montreal, QC, Canada; 3Radiation Oncology, McGill University, Montreal, QC, Canada; 4Radiation Oncology, McGill University, Montreal, QC, Canada.

P-116
HDR AND LDR BRACHYTHERAPY FOR FAVORABLE PROSTATE CANCER: AN ANALYSIS BASED ON DIFFERENT BIOCHEMICAL FAILURE DEFINITIONS
K Kenneth Chao, MD, Carlos E Vargas, MD, Dwight L Fitch, MD, Thomas Boike, Courtney Byrd, Daniel J Krauss, MD, Gary S Gustafson, MD, Frank A Vicini, MD FACR, Alvaro A Martinez, MD FACR, Larry L Kestin, MD. 1 Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.

Benign

P-117
FIRST-IN-MAN EXPERIENCE WITH THE THERASIGHT™ OCULAR BRACHYTHERAPY SYSTEM FOR TREATMENT OF AMD
Ian R Crocker, MD, Thomas Ciulla, MD, Elizabeth K Butker, M.Sc., Gabriela Burian, MD, Baker Hubbard III, MD. 1 Radiation Oncology, Emory University School of Medicine, Atlanta, GA; 2 Ophthalmology, Midwest Eye Institute, Indianapolis, IN; 3 Ophthalmology, Emory University School of Medicine, Atlanta, GA.

Colorectal

P-118
ROLE OF INTERSTITIAL BRACHYTHERAPY FOR SPHINCTER PRESERVATION IN PATIENTS WITH LOW LYING RECTAL AND ANAL CANCERS
Moataz N El-Ghamry, M.D., Subir Nag, M.D., John Winston, M.D., Mark Arnold, M.D. 1 Radiation Oncology, Ohio State University, James Cancer Hospital, Columbus, OH; 2 General Surgery, Ohio State University Medical Center, Columbus, OH.

P-119
THE FEASIBILITY OF HIGH-DOSE-RATE (HDR) INTERSTITIAL BRACHYTHERAPY FOR PREVIOUSLY IRRADIATED RECURRENT ANAL CARCINOMA
Tony Y Eng, MD. 1, 2 1Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX; 2 Department of Radiation Oncology, Cancer Therapy and Research Center, San Antonio, TX.

CNS

P-120
MANAGEMENT OF BRAIN TUMORS WITH THE GLIASITE™RADIATION THERAPY SYSTEM: THE EMMORY EXPERIENCE
Cynthia J Bryant, MD, Jeffrey J Olson, MD, Elizabeth K Butker, MS, Robert B Marcus, MD, Ian R Crocker, MD 1 Radiation Oncology, Emory University School of Medicine, Atlanta, GA; 2 Neurosurgery, Emory University School of Medicine, Atlanta, GA.

P-121
RISK FACTORS FOR LOCAL INFECTIOUS COMPLICATIONS OF GLIASITE BALLOON BRACHYTHERAPY FOR BRAIN TUMORS: IMPLICATIONS FOR CLINICAL PRACTICE
Rajni Singh, DO, David L Sherr, MD, Dattatreyudu Nori, MD. 1 Radiation Oncology, New York Weill Cornell Medical Center, New York, NY.
Biology

P-122
TIMING OF HDR BOOST AND EXTERNAL BEAM RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: A SERIES OF EXPLORATORY CALCULATIONS INVOLVING HYPOXIA
Giuseppe Sanguineti, MD,1 Alan Nahum, PhD.2 Radiation Oncology, University of Texas Medical Branch, Galveston, TX; 2Physics, Clatterbridge Centre for Oncology, Bebington, United Kingdom.

Soft Tissue Sarcoma

P-123
INTERSTITIAL BRACHYTHERAPY FOR THE PERIOPERATIVE TREATMENT OF SOFT TISSUE SARCOMAS WITH POSITIVE OR CLOSE MARGINS
Shalin J Shah, MD,1 Adnan Danish, MD,1 James Butler, MD,1 Jonathan Beitler, MD,2 Madhur Garg, MD.1
1Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY; 2Department of Radiation Oncology, Staten Island University Hospital, Staten Island, NY.

P-125
FOLLOWUP OF 27 PATIENTS TREATED WITH LDR CF-252
Mark J Rivard, Ph.D.,1 John E Mignano, M.D., Ph.D.,1 Rajiv Patel, M.D.,2 Renu K Sharma, M.Sc.2 1Radiation Oncology, Tufts-New England Medical Center, Boston, MA; 2Radiation Oncology, Harper Hospital, Detroit, MI.

P-126
RESECTION AND BRACHYTHERAPY FOR RECURRENT SOFT TISSUE SARCOMA ARISING IN A PREVIOUSLY IRRADIATED FIELD
Mylin A Torres, MD,1 Matthew T Ballo, MD,1 Charles E Butler, MD,2 Barry W Feig, MD,3 Howard N Langstein, MD,2 Valerae O Lewis, MD,4 Peter W Pisters, MD,3 Gunar K Zagars, MD.1 Radiation Oncology, MD Anderson Cancer Center, Houston, TX; 2Plastic Surgery, MD Anderson Cancer Center, Houston, TX; 3Surgical Oncology, MD Anderson Cancer Center, Houston, TX; 4Orthopedic Oncology, MD Anderson Cancer Center, Houston, TX.

Other

P-127
THE APPLICATION OF 90Sr / 90Y FOR THE PREVENTION OF ABDOMINAL ADHESIONS
Samuel J Rhoades IV, MS,1,2 Melissa M Blough, PhD,1,2 James M Hevezi, PhD,1,2 Radiological Sciences, University of Texas Health Science Center, San Antonio, TX; 2Medical Physics, Cancer Therapy & Research Center, San Antonio, TX
**Future Meetings**

**2005 ABS**

Gyn School

July 29-30, 2005
Knickerbocker Hotel
Chicago, Illinois

**2006 ABS**

Annual Meeting

May 10–12, 2006
Philadelphia Marriott
Philadelphia, Pennsylvania

**2007 ABS**

Annual Meeting

April 29–May 1, 2007
Sheraton Hotel
Chicago, Illinois

**2008**

ABS/GEC–ESTRO Joint Meeting
Hyatt Regency San Francisco
Floor Plans